Harpeth Capital Research
Advisory Approach
Harpeth Capital operates as a boutique, relationship-focused investment banking firm specializing in middle-market M&A advisory and capital raising. The firm's thesis is that middle-market business owners and their boards deserve institutional-quality investment banking services typically reserved for much larger companies—with senior-level attention, deep industry expertise, and unencumbered advice from a truly independent firm. Founded in 1999, Harpeth Capital serves founder-owned, family-led, and publicly-traded companies with enterprise values ranging from $5M to $500M+, though with particular strength in the $25M-$250M range. The firm's sweet spot is businesses in transition: founders seeking optimal exit strategies, boards navigating strategic alternatives, and companies managing complex recapitalizations, reorganizations, or going-private transactions. The firm explicitly positions itself as the antithesis of "one-size-fits-all" banking, dedicating time to explore all viable paths—auction processes, negotiated sales, structured recaps, or strategic partnerships—before recommending the optimal approach. Long-term relationships are foundational: Harpeth often serves clients years in advance of a transaction, providing valuation insights, capital-raising advice, or strategic counsel, then continues to support clients post-close.
Healthcare Specialization
Harpeth Capital has emerged as a significant player in healthcare investment banking, with deep expertise spanning provider-based services, healthcare IT, behavioral health, physician practice management (PPM), revenue cycle management, and healthcare technology platforms. The firm explicitly touts its healthcare focus as a core competitive advantage, maintaining extensive networks with healthcare strategics, PE buyers, and institutional capital sources. Recent transactions showcase the breadth: advising Regional Health Properties (a micro-cap healthcare REIT) on its transformative merger with SunLink Health Systems (August 2025), the acquisition of MDsave—a leading healthcare marketplace platform—by Tendo (September 2023), the merger of SunCrest Healthcare with Omni Home Care (March 2018), and institutional roles in healthcare capital raises including three rounds of the Montecito Medical Physicians fund ($485.7M in 2025, $307.2M in 2021, $82.5M in 2020, and $55.6M in 2019). These transactions demonstrate both breadth—from home care operators to healthcare technology companies—and depth, with the firm serving as exclusive financial advisor, fairness opinion provider, or lead placement agent on complex, multi-stakeholder transactions.
Sector & Industry Focus
While healthcare dominates the firm's M&A and capital raising activities, Harpeth maintains active advisory practices in manufacturing, industrial distribution, business services, and consumer/retail. The firm's deal history reveals particular expertise in: (1) healthcare technology and health systems transactions (MDsave, behavioral health platforms); (2) business process outsourcing and document management (Statement Rendering Solutions acquired by Kubra for an undisclosed premium, CORT Business Services); (3) home health and post-acute care networks; (4) ASC (ambulatory surgery center) platforms and healthcare real estate; and (5) industrial and business services where the firm has advised on transactions spanning manufacturing, distribution, and energy sectors. The firm also maintains a venture capital arm, Harpeth Ventures, which takes minority stakes in portfolio companies (evidenced by equity checks in SurgNet, Venteur, and other healthcare tech platforms). This hybrid banking + venture model differentiates Harpeth from pure advisory firms and signals willingness to take capital-at-risk on transactions where conviction is high.
Advisory Track Record
Harpeth Capital reports 125+ transactions closed with $6B+ in aggregate transaction value. While individual deal sizes span from several million to several hundred million dollars, the firm gravitates toward lower-middle-market transactions ($5M-$100M+ TEV), where advisory expertise, market access, and buyer relationships create the most value. The firm's deal experience spans sell-side advisory (auction processes, confidential sale processes), buy-side / management buyout advisory, merger facilitation (combining two operating companies), going-private advisory (micro-cap public companies returning to private ownership), and capital raising (both debt and equity). Recent high-profile transactions include the Regional Health Properties / SunLink merger, where Harpeth advised the Board of Directors; MDsave's acquisition by Tendo following years of growth capital placements; and placement agent roles on Montecito Medical Physicians funds, which raised nearly $1.2B across multiple vintages. This combination of M&A advisory, capital raising, and principal investing positions Harpeth as both a banker and a business development partner, not merely a transaction facilitator.
Process & Fee Structure
Harpeth's engagement model emphasizes institutional-quality process management without the overhead of a bulge-bracket firm. Sell-side processes typically include: comprehensive "packaging" of the opportunity (management presentation materials, executive summaries, sell-side positioning); strategic buyer identification and outreach (to financial and/or strategic buyers aligned with the company's profile); negotiation support and deal structure advice; and post-close advisory. The firm explicitly positions buy-side processes as more selective, cautioning clients about the risks of "limited process" engagements. Buy-side advisory includes target identification, valuation analysis, negotiation support, and integration planning. For capital raises, Harpeth operates as a placement agent, leveraging relationships with institutional investors, family offices, and fund managers to source capital at optimal terms. Fee structures are not publicly disclosed but market-standard for boutique M&A advisory: likely modified Lehman (or negotiated percentage) on sell-side M&A, combined with a retainer structure for larger engagement. The firm's emphasis on long-term relationships suggests it is willing to invest senior time early in engagements before formal mandates, with the expectation of deeper, multi-year relationships.
Buyer Network & Deal Buyer Patterns
From the transaction history visible on the firm's website, Harpeth demonstrates strong relationships with: (1) Private equity firms (Clairvest Equity Partners, New Mainstream Capital, Ridgemont Equity Partners, Aldine partners); (2) Strategic acquirers in healthcare (Tendo, Perimeter Healthcare, Health systems); (3) Family offices and institutional capital providers (Vinik Family Office documented in SurgNet capital raise); (4) Specialized funds (Montecito Medical Physicians fund series, Clarity Ventures Veterinary Fund); and (5) Large industrials (Wesco Financial / Berkshire Hathaway ecosystem on CORT transaction). The firm's capital-raising mandate on Montecito Medical funds—closing multiple $50M-$500M+ institutional funds—signals deep institutional relationships and credibility with LPs. Deal buyers span from micro-PE shops to Fortune 500 acquirers, though the firm's sweet spot appears to be lower-middle-market PE buyers and strategic health systems seeking bolt-on acquisitions.
Competitive Positioning
Harpeth Capital's competitive differentiation rests on: (1) Senior-level attention: Managing Directors and the CEO direct client relationships, not junior associates. (2) Healthcare expertise: Unmatched in Nashville market with 25+ years of healthcare M&A and capital-raising experience across multiple healthcare subsectors. (3) Independence: No conflicts from proprietary research, sales/trading, or other divisions. Advice is unencumbered and client-centric. (4) Institutional relationships: Deep networks with healthcare PE, health systems, institutional capital (evidenced by $1.2B+ in Montecito placements). (5) Process sophistication: Institutional M&A process management (buyer identification, data rooms, negotiation support) at a mid-market price point. (6) Capital access: Hybrid banking + venture model allows the firm to co-invest in transactions, signaling conviction and providing additional capital sourcing. (7) Long-term partnership model: The firm explicitly markets itself as a multi-year advisor, not a transaction shop—retaining clients across multiple deals and lifecycle stages.
Not a Fit If...
Harpeth Capital declines engagements in the following scenarios: (1) Transactions below ~$5M TEV (firm lacks internal economies of scale); (2) "Limited process" sellers seeking quick, confidential negotiations with a single buyer (the firm's value is in exhaustive outreach); (3) Distressed situations requiring immediate capital (though the firm does have restructuring expertise); (4) Sellers unwilling to invest time in comprehensive process management (which requires 6-12 months); (5) Publicly-traded large-cap companies (firm lacks scale for $1B+ deals); (6) Commoditized advisory (price-sensitive, low-touch mandates where relationships don't matter).
Team & Organizational Capacity
The firm is led by Charles W. "Chuck" Byrge, II, CEO and President, a Nashville native with 30+ years of investment banking experience spanning SunTrust Equitable Securities (now Truist), Morgan Keegan, NationsBanc Capital Markets, and FTN Financial. Byrge is a CFA charterholder, former CPA, and holds an MBA from Vanderbilt's Owen Graduate School of Management, where he serves on the Emeritus Board. He actively directs all major client relationships and strategic initiatives. Adam A. Landa, Managing Director, brings 30+ years of investment banking, accounting, and corporate finance experience from FTN Financial and Truist. Landa is a former CPA, holds Series 7 & 63 registrations, and serves as operational co-lead on major transactions. Supporting team members include Chris Decker (Director), Zachary Varner (Vice President), and Senior Advisors George C. Gaines, Jr., Angela R. Stanley, and Charles K. Woodworth. The firm also maintains an Advisory Board consisting of prominent Nashville business and healthcare leaders, bringing external expertise and relationship capital. Office operations are supported by Susan Hanson, Office Manager. Total headcount is approximately 8-10 full-time professionals, positioning the firm as lean but highly specialized.
Geographic Coverage & Market Position
Harpeth Capital operates from headquarters in Nashville, Tennessee, with national reach for transactions. The firm explicitly markets itself as nationwide in scope, having completed transactions across the U.S. healthcare, industrial, and business services landscapes. However, Nashville is the firm's home base and hub of operation, and the firm appears to maintain particular strength in Southeast regional transactions. The firm's Nashville domicile is a competitive asset in the healthcare vertical—Nashville is a recognized healthcare innovation and investment hub, home to prominent HCA, Community Health Systems, and numerous smaller health systems and healthcare PE platforms.
Regulatory Status & Compliance
Harpeth Capital is FINRA-registered through Harpeth Securities, LLC (member FINRA/SIPC). The firm is subject to standard investment banking regulatory oversight. Key team members, including Adam Landa, hold FINRA Series 7 & 63 registrations. The firm maintains regulatory disclosures and BrokerCheck profiles accessible to the public, and explicitly links to these on its website, signaling compliance transparency.
Summary
Harpeth Capital is a specialized, relationship-driven boutique investment bank with 25+ years of institutional presence in the middle market. Founder-led, led by veteran bankers with credibility in healthcare, industrial, and business services sectors, the firm combines pure advisory services (M&A, capital raising) with a venture capital arm and willingness to co-invest in portfolio companies. The firm's sweet spot is founder/family-owned businesses and micro-cap public companies seeking institutional-quality advisory at a boutique price point, with particular strength in healthcare transactions. Recent activity (Regional Health Properties merger, MDsave acquisition, Montecito Medical capital raises) demonstrates continued momentum and credibility with institutional capital sources and strategic acquirers.